Loading…

Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway

Dexmedetomidine (Dex) is widely used for sedation in intensive care units and can be used as an adjunct to anesthetics. Previous studies have demonstrated that Dex has anti‐inflammatory property. In this study, we aim to explore the potential therapeutic effects and mechanisms of Dex on lipopolysacc...

Full description

Saved in:
Bibliographic Details
Published in:Fundamental & clinical pharmacology 2015-10, Vol.29 (5), p.462-471
Main Authors: Xu, Yingzhen, Zhang, Ruyi, Li, Chunli, Yin, Xue, Lv, Changjun, Wang, Yaoqi, Zhao, Wenxiang, Zhang, Xiuli
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183
cites cdi_FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183
container_end_page 471
container_issue 5
container_start_page 462
container_title Fundamental & clinical pharmacology
container_volume 29
creator Xu, Yingzhen
Zhang, Ruyi
Li, Chunli
Yin, Xue
Lv, Changjun
Wang, Yaoqi
Zhao, Wenxiang
Zhang, Xiuli
description Dexmedetomidine (Dex) is widely used for sedation in intensive care units and can be used as an adjunct to anesthetics. Previous studies have demonstrated that Dex has anti‐inflammatory property. In this study, we aim to explore the potential therapeutic effects and mechanisms of Dex on lipopolysaccharide (LPS)‐induced acute lung injury (ALI) in mice. To induce ALI, mice were intraperitoneally injected with LPS, while Dex was treated 1 h before LPS injection. The inflammation of lung tissues was evaluated by HE stain, and bronchoalveolar lavage fluid (BALF) was obtained after 6 h to measure protein concentrations. We also used an enzyme‐linked immunosorbent assay to detect the secretion levels of proinflammatory cytokines in the serum. Western blotting method was adopted to observe changes in mitogen‐activated protein kinases and downstream nuclear transcription factors. The results showed that pretreatment with Dex considerably reduced neutrophil infiltration and pulmonary edema, and significantly reduced protein concentrations in the BALF, as well as suppressed LPS‐induced elevation of proinflammatory cytokines (TNF‐α and IL‐1β) in the serum. In addition, we observed that the molecular mechanism of Dex‐mediated anti‐inflammation is associated with decreasing phosphorylation of MKK4, MMK3/6, ERK1/2, p38MAPK, and JNK, and diminishing activation of Elk‐1, c‐Jun, and ATF‐2. Dex could attenuate ALI induced by LPS in mice, and this effect may be mediated through the inhibition of MAPK pathway.
doi_str_mv 10.1111/fcp.12138
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1713527838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1713527838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183</originalsourceid><addsrcrecordid>eNp1kEtv1TAQRi0EopfCgj-AvIRFWj8SP5bVvfShFugCytJynLmNSxKnsUObf1-X23bHbEaaOfNpdBD6SMkBzXW4deMBZZSrV2hFS8kKxYh4jVZECllwregeehfjDSFUEireoj0mGKWlrlbo7wbue2gghd43fgBsU4Jhtgkitm5OgLt5uMZ-uJmnJbdmdtDgesGdH8MYuiVa51o7-QbyFvdhjoBTO4X5us2D1tc--TDgsMXfji7P8WhTe2eX9-jN1nYRPjz1ffTr-OvP9Wlx8ePkbH10UbiSaVVoy4XTTtYlJVKDVFYqXZcVKaFxdeWIcLV1gsk80IzVTVXVggC3SmtOqeL76PMud5zC7Qwxmd5HB11nB8ivGiopr5hU_BH9skPdFGKcYGvGyfd2Wgwl5lGzyZrNP82Z_fQUO9fZ3gv57DUDhzvgznew_D_JHK8vnyOL3YWPCe5fLuz0xwjJZWV-fz8xV5vNFT09F0bxB_VNl3Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1713527838</pqid></control><display><type>article</type><title>Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Xu, Yingzhen ; Zhang, Ruyi ; Li, Chunli ; Yin, Xue ; Lv, Changjun ; Wang, Yaoqi ; Zhao, Wenxiang ; Zhang, Xiuli</creator><creatorcontrib>Xu, Yingzhen ; Zhang, Ruyi ; Li, Chunli ; Yin, Xue ; Lv, Changjun ; Wang, Yaoqi ; Zhao, Wenxiang ; Zhang, Xiuli</creatorcontrib><description>Dexmedetomidine (Dex) is widely used for sedation in intensive care units and can be used as an adjunct to anesthetics. Previous studies have demonstrated that Dex has anti‐inflammatory property. In this study, we aim to explore the potential therapeutic effects and mechanisms of Dex on lipopolysaccharide (LPS)‐induced acute lung injury (ALI) in mice. To induce ALI, mice were intraperitoneally injected with LPS, while Dex was treated 1 h before LPS injection. The inflammation of lung tissues was evaluated by HE stain, and bronchoalveolar lavage fluid (BALF) was obtained after 6 h to measure protein concentrations. We also used an enzyme‐linked immunosorbent assay to detect the secretion levels of proinflammatory cytokines in the serum. Western blotting method was adopted to observe changes in mitogen‐activated protein kinases and downstream nuclear transcription factors. The results showed that pretreatment with Dex considerably reduced neutrophil infiltration and pulmonary edema, and significantly reduced protein concentrations in the BALF, as well as suppressed LPS‐induced elevation of proinflammatory cytokines (TNF‐α and IL‐1β) in the serum. In addition, we observed that the molecular mechanism of Dex‐mediated anti‐inflammation is associated with decreasing phosphorylation of MKK4, MMK3/6, ERK1/2, p38MAPK, and JNK, and diminishing activation of Elk‐1, c‐Jun, and ATF‐2. Dex could attenuate ALI induced by LPS in mice, and this effect may be mediated through the inhibition of MAPK pathway.</description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><identifier>DOI: 10.1111/fcp.12138</identifier><identifier>PMID: 26211495</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>acute lung injury ; Acute Lung Injury - chemically induced ; Acute Lung Injury - enzymology ; Acute Lung Injury - genetics ; Acute Lung Injury - pathology ; Acute Lung Injury - prevention &amp; control ; Animals ; Anti-Inflammatory Agents - pharmacology ; Bronchoalveolar Lavage Fluid - chemistry ; Cytokines - metabolism ; Cytoprotection ; dexmedetomidine ; Dexmedetomidine - pharmacology ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Enzyme Activation ; inflammation ; Inflammation Mediators - metabolism ; lipopolysaccharide ; Lipopolysaccharides ; Lung - drug effects ; Lung - enzymology ; Lung - pathology ; Male ; MAP Kinase Signaling System - drug effects ; Mice ; mitogen-activated protein kinase ; Mitogen-Activated Protein Kinases - metabolism ; Neutrophil Infiltration - drug effects ; Phosphorylation ; Pulmonary Edema - chemically induced ; Pulmonary Edema - enzymology ; Pulmonary Edema - prevention &amp; control ; Time Factors ; Transcription Factors - genetics ; Transcription Factors - metabolism ; Transcription, Genetic - drug effects</subject><ispartof>Fundamental &amp; clinical pharmacology, 2015-10, Vol.29 (5), p.462-471</ispartof><rights>2015 Société Française de Pharmacologie et de Thérapeutique</rights><rights>2015 Société Française de Pharmacologie et de Thérapeutique.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183</citedby><cites>FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26211495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Yingzhen</creatorcontrib><creatorcontrib>Zhang, Ruyi</creatorcontrib><creatorcontrib>Li, Chunli</creatorcontrib><creatorcontrib>Yin, Xue</creatorcontrib><creatorcontrib>Lv, Changjun</creatorcontrib><creatorcontrib>Wang, Yaoqi</creatorcontrib><creatorcontrib>Zhao, Wenxiang</creatorcontrib><creatorcontrib>Zhang, Xiuli</creatorcontrib><title>Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway</title><title>Fundamental &amp; clinical pharmacology</title><addtitle>Fundam Clin Pharmacol</addtitle><description>Dexmedetomidine (Dex) is widely used for sedation in intensive care units and can be used as an adjunct to anesthetics. Previous studies have demonstrated that Dex has anti‐inflammatory property. In this study, we aim to explore the potential therapeutic effects and mechanisms of Dex on lipopolysaccharide (LPS)‐induced acute lung injury (ALI) in mice. To induce ALI, mice were intraperitoneally injected with LPS, while Dex was treated 1 h before LPS injection. The inflammation of lung tissues was evaluated by HE stain, and bronchoalveolar lavage fluid (BALF) was obtained after 6 h to measure protein concentrations. We also used an enzyme‐linked immunosorbent assay to detect the secretion levels of proinflammatory cytokines in the serum. Western blotting method was adopted to observe changes in mitogen‐activated protein kinases and downstream nuclear transcription factors. The results showed that pretreatment with Dex considerably reduced neutrophil infiltration and pulmonary edema, and significantly reduced protein concentrations in the BALF, as well as suppressed LPS‐induced elevation of proinflammatory cytokines (TNF‐α and IL‐1β) in the serum. In addition, we observed that the molecular mechanism of Dex‐mediated anti‐inflammation is associated with decreasing phosphorylation of MKK4, MMK3/6, ERK1/2, p38MAPK, and JNK, and diminishing activation of Elk‐1, c‐Jun, and ATF‐2. Dex could attenuate ALI induced by LPS in mice, and this effect may be mediated through the inhibition of MAPK pathway.</description><subject>acute lung injury</subject><subject>Acute Lung Injury - chemically induced</subject><subject>Acute Lung Injury - enzymology</subject><subject>Acute Lung Injury - genetics</subject><subject>Acute Lung Injury - pathology</subject><subject>Acute Lung Injury - prevention &amp; control</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Bronchoalveolar Lavage Fluid - chemistry</subject><subject>Cytokines - metabolism</subject><subject>Cytoprotection</subject><subject>dexmedetomidine</subject><subject>Dexmedetomidine - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Enzyme Activation</subject><subject>inflammation</subject><subject>Inflammation Mediators - metabolism</subject><subject>lipopolysaccharide</subject><subject>Lipopolysaccharides</subject><subject>Lung - drug effects</subject><subject>Lung - enzymology</subject><subject>Lung - pathology</subject><subject>Male</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>Mice</subject><subject>mitogen-activated protein kinase</subject><subject>Mitogen-Activated Protein Kinases - metabolism</subject><subject>Neutrophil Infiltration - drug effects</subject><subject>Phosphorylation</subject><subject>Pulmonary Edema - chemically induced</subject><subject>Pulmonary Edema - enzymology</subject><subject>Pulmonary Edema - prevention &amp; control</subject><subject>Time Factors</subject><subject>Transcription Factors - genetics</subject><subject>Transcription Factors - metabolism</subject><subject>Transcription, Genetic - drug effects</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kEtv1TAQRi0EopfCgj-AvIRFWj8SP5bVvfShFugCytJynLmNSxKnsUObf1-X23bHbEaaOfNpdBD6SMkBzXW4deMBZZSrV2hFS8kKxYh4jVZECllwregeehfjDSFUEireoj0mGKWlrlbo7wbue2gghd43fgBsU4Jhtgkitm5OgLt5uMZ-uJmnJbdmdtDgesGdH8MYuiVa51o7-QbyFvdhjoBTO4X5us2D1tc--TDgsMXfji7P8WhTe2eX9-jN1nYRPjz1ffTr-OvP9Wlx8ePkbH10UbiSaVVoy4XTTtYlJVKDVFYqXZcVKaFxdeWIcLV1gsk80IzVTVXVggC3SmtOqeL76PMud5zC7Qwxmd5HB11nB8ivGiopr5hU_BH9skPdFGKcYGvGyfd2Wgwl5lGzyZrNP82Z_fQUO9fZ3gv57DUDhzvgznew_D_JHK8vnyOL3YWPCe5fLuz0xwjJZWV-fz8xV5vNFT09F0bxB_VNl3Y</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Xu, Yingzhen</creator><creator>Zhang, Ruyi</creator><creator>Li, Chunli</creator><creator>Yin, Xue</creator><creator>Lv, Changjun</creator><creator>Wang, Yaoqi</creator><creator>Zhao, Wenxiang</creator><creator>Zhang, Xiuli</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway</title><author>Xu, Yingzhen ; Zhang, Ruyi ; Li, Chunli ; Yin, Xue ; Lv, Changjun ; Wang, Yaoqi ; Zhao, Wenxiang ; Zhang, Xiuli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>acute lung injury</topic><topic>Acute Lung Injury - chemically induced</topic><topic>Acute Lung Injury - enzymology</topic><topic>Acute Lung Injury - genetics</topic><topic>Acute Lung Injury - pathology</topic><topic>Acute Lung Injury - prevention &amp; control</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Bronchoalveolar Lavage Fluid - chemistry</topic><topic>Cytokines - metabolism</topic><topic>Cytoprotection</topic><topic>dexmedetomidine</topic><topic>Dexmedetomidine - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Enzyme Activation</topic><topic>inflammation</topic><topic>Inflammation Mediators - metabolism</topic><topic>lipopolysaccharide</topic><topic>Lipopolysaccharides</topic><topic>Lung - drug effects</topic><topic>Lung - enzymology</topic><topic>Lung - pathology</topic><topic>Male</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>Mice</topic><topic>mitogen-activated protein kinase</topic><topic>Mitogen-Activated Protein Kinases - metabolism</topic><topic>Neutrophil Infiltration - drug effects</topic><topic>Phosphorylation</topic><topic>Pulmonary Edema - chemically induced</topic><topic>Pulmonary Edema - enzymology</topic><topic>Pulmonary Edema - prevention &amp; control</topic><topic>Time Factors</topic><topic>Transcription Factors - genetics</topic><topic>Transcription Factors - metabolism</topic><topic>Transcription, Genetic - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Yingzhen</creatorcontrib><creatorcontrib>Zhang, Ruyi</creatorcontrib><creatorcontrib>Li, Chunli</creatorcontrib><creatorcontrib>Yin, Xue</creatorcontrib><creatorcontrib>Lv, Changjun</creatorcontrib><creatorcontrib>Wang, Yaoqi</creatorcontrib><creatorcontrib>Zhao, Wenxiang</creatorcontrib><creatorcontrib>Zhang, Xiuli</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fundamental &amp; clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Yingzhen</au><au>Zhang, Ruyi</au><au>Li, Chunli</au><au>Yin, Xue</au><au>Lv, Changjun</au><au>Wang, Yaoqi</au><au>Zhao, Wenxiang</au><au>Zhang, Xiuli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway</atitle><jtitle>Fundamental &amp; clinical pharmacology</jtitle><addtitle>Fundam Clin Pharmacol</addtitle><date>2015-10</date><risdate>2015</risdate><volume>29</volume><issue>5</issue><spage>462</spage><epage>471</epage><pages>462-471</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><abstract>Dexmedetomidine (Dex) is widely used for sedation in intensive care units and can be used as an adjunct to anesthetics. Previous studies have demonstrated that Dex has anti‐inflammatory property. In this study, we aim to explore the potential therapeutic effects and mechanisms of Dex on lipopolysaccharide (LPS)‐induced acute lung injury (ALI) in mice. To induce ALI, mice were intraperitoneally injected with LPS, while Dex was treated 1 h before LPS injection. The inflammation of lung tissues was evaluated by HE stain, and bronchoalveolar lavage fluid (BALF) was obtained after 6 h to measure protein concentrations. We also used an enzyme‐linked immunosorbent assay to detect the secretion levels of proinflammatory cytokines in the serum. Western blotting method was adopted to observe changes in mitogen‐activated protein kinases and downstream nuclear transcription factors. The results showed that pretreatment with Dex considerably reduced neutrophil infiltration and pulmonary edema, and significantly reduced protein concentrations in the BALF, as well as suppressed LPS‐induced elevation of proinflammatory cytokines (TNF‐α and IL‐1β) in the serum. In addition, we observed that the molecular mechanism of Dex‐mediated anti‐inflammation is associated with decreasing phosphorylation of MKK4, MMK3/6, ERK1/2, p38MAPK, and JNK, and diminishing activation of Elk‐1, c‐Jun, and ATF‐2. Dex could attenuate ALI induced by LPS in mice, and this effect may be mediated through the inhibition of MAPK pathway.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>26211495</pmid><doi>10.1111/fcp.12138</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0767-3981
ispartof Fundamental & clinical pharmacology, 2015-10, Vol.29 (5), p.462-471
issn 0767-3981
1472-8206
language eng
recordid cdi_proquest_miscellaneous_1713527838
source Wiley-Blackwell Read & Publish Collection
subjects acute lung injury
Acute Lung Injury - chemically induced
Acute Lung Injury - enzymology
Acute Lung Injury - genetics
Acute Lung Injury - pathology
Acute Lung Injury - prevention & control
Animals
Anti-Inflammatory Agents - pharmacology
Bronchoalveolar Lavage Fluid - chemistry
Cytokines - metabolism
Cytoprotection
dexmedetomidine
Dexmedetomidine - pharmacology
Disease Models, Animal
Dose-Response Relationship, Drug
Enzyme Activation
inflammation
Inflammation Mediators - metabolism
lipopolysaccharide
Lipopolysaccharides
Lung - drug effects
Lung - enzymology
Lung - pathology
Male
MAP Kinase Signaling System - drug effects
Mice
mitogen-activated protein kinase
Mitogen-Activated Protein Kinases - metabolism
Neutrophil Infiltration - drug effects
Phosphorylation
Pulmonary Edema - chemically induced
Pulmonary Edema - enzymology
Pulmonary Edema - prevention & control
Time Factors
Transcription Factors - genetics
Transcription Factors - metabolism
Transcription, Genetic - drug effects
title Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T22%3A05%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dexmedetomidine%20attenuates%20acute%20lung%20injury%20induced%20by%20lipopolysaccharide%20in%20mouse%20through%20inhibition%20of%20MAPK%20pathway&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Xu,%20Yingzhen&rft.date=2015-10&rft.volume=29&rft.issue=5&rft.spage=462&rft.epage=471&rft.pages=462-471&rft.issn=0767-3981&rft.eissn=1472-8206&rft_id=info:doi/10.1111/fcp.12138&rft_dat=%3Cproquest_cross%3E1713527838%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1713527838&rft_id=info:pmid/26211495&rfr_iscdi=true